Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Vandetanib (ZD6474; ZACTIMA, AstraZeneca) is a once-daily, orally available agent with potential for use in a number of solid tumor types. Vandetanib targets key signaling pathways in cancer by inhibiting VEGFR-dependent tumor angiogenesis, and EGFR- and RET-dependent tumor cell proliferation and survival. Phase I studies showed vandetanib to be generally well tolerated at doses of < or = 300 mg/day, with a pharmacokinetic profile that supports once-daily oral administration. Phase II evaluation of vandetanib in patients with advanced refractory NSCLC has demonstrated improvements in progression-free survival both as monotherapy (versus gefitinib) and in combination with docetaxel (versus docetaxel alone). These positive outcomes have led to the initiation of Phase III trials of vandetanib in advanced NSCLC. Clinical development is also ongoing in other tumor types and encouraging evidence of antitumor activity has been reported in patients with metastatic hereditary medullary thyroid cancer.

Original publication

DOI

10.1517/13543784.16.2.239

Type

Journal article

Journal

Expert Opin Investig Drugs

Publication Date

02/2007

Volume

16

Pages

239 - 249

Keywords

Administration, Oral, Angiogenesis Inhibitors, Animals, Antineoplastic Agents, Drug Delivery Systems, Humans, Neovascularization, Pathologic, Piperidines, Protein Kinase Inhibitors, Quinazolines, Receptor Protein-Tyrosine Kinases, Signal Transduction